Show simple item record

dc.contributor.authorHarshman, L Cen_US
dc.contributor.authorFougeray, Ren_US
dc.contributor.authorChoueiri, T Ken_US
dc.contributor.authorSchutz, F Aen_US
dc.contributor.authorSalhi, Yen_US
dc.contributor.authorRosenberg, J Een_US
dc.contributor.authorBellmunt, Jen_US
dc.date.accessioned2014-12-02T21:29:05Z
dc.date.issued2013en_US
dc.identifier.citationHarshman, L C, R Fougeray, T K Choueiri, F A Schutz, Y Salhi, J E Rosenberg, and J Bellmunt. 2013. “The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine.” British Journal of Cancer 109 (10): 2548-2553. doi:10.1038/bjc.2013.617. http://dx.doi.org/10.1038/bjc.2013.617.en
dc.identifier.issn0007-0920en
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:13454818
dc.description.abstractBackground: A phase III trial demonstrated an overall survival advantage with the addition of vinflunine to best supportive care (BSC) in platinum-refractory advanced urothelial cancer. We subsequently examined the impact of an additional 2 years of survival follow-up and evaluated the influence of first-line platinum therapy on survival. Methods: The 357 eligible patients from the phase III study were categorised into two cohorts depending on prior cisplatin treatment: cisplatin or non-cisplatin. Survival was calculated using the Kaplan–Meier method. Results: The majority had received prior cisplatin (70.3%). Survival was higher in the cisplatin group (HR: 0.76; CI 95% 0.58–0.99; P=0.04) irrespective of treatment arm. Multivariate analysis including known prognostic factors (liver involvement, haemoglobin, performance status) and prior platinum administration did not show an independent effect of cisplatin. Vinflunine reduced the risk of death by 24% in the cisplatin-group (HR: 0.76; CI 95% 0.58–0.99; P=0.04) and by 35% in non-cisplatin patients (HR: 0.65; CI 95% 0.41–1.04; P=0.07). Interpretation: Differences in prognostic factors between patients who can receive prior cisplatin and those who cannot may explain the survival differences in patients who undergo second line therapy. Prior cisplatin administration did not diminish the subsequent benefit of vinflunine over BSC.en
dc.language.isoen_USen
dc.publisherNature Publishing Groupen
dc.relation.isversionofdoi:10.1038/bjc.2013.617en
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833211/pdf/en
dash.licenseLAAen_US
dc.subjectvinflunineen
dc.subjecturothelial canceren
dc.subjectcisplatinen
dc.subjectplatinumen
dc.subjectsurvivalen
dc.titleThe impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunineen
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalBritish Journal of Canceren
dc.date.available2014-12-02T21:29:05Z
dc.identifier.doi10.1038/bjc.2013.617*


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record